Caller reporting discrepant high inratio values (b)(6) 2014, inratio 6.2, lab 3.2, tests performed within three hours.(b)(6) 2015, inratio 5.7.(b)(6) 2015, lab 3.2, one day between tests performed on (b)(6) 2015.Patient's therapeutic range 2.5 - 3.5.No coumadin dosage changes between receiving the inratio result and the corresponding lab result.Patient self tester went to the er on (b)(6) 2015 after experiencing severe headaches on (b)(6) 2015.Inr (venous draw) was taken upon admittance.Patient admitted and diagnosed with brain inflammation.Patient hospitalized for one week during which the patient was taken off coumadin and placed on lovenox.Patient underwent brain surgery for the inflammation during hospitalization, no exact date available.Patient was released to home 1 week after admittance, patient currently comfortable at home.Requested discharge diagnosis.Per patient, no discharge diagnosis available.Patient stated that physician had stated the inflammation was consistent with severe trauma to the head (a contusion), however patient states that no trauma was experienced prior to hospitalization.Patient currently taking lovenox but will be bridged back to coumadin shortly.No additional information available.
|
Investigation conclusion: it is indicated that product is not returning for evaluation.Since the product associated with the complaint was not returned, a review of in-house testing was performed.Retain strip testing results met both accuracy and repeatability criteria.The products performed as expected and no product deficiencies were observed.The manufacturing records for the lot were reviewed.The non-conformance associated with this lot was not relevant to the initial complaint and does not affect product performance.Root cause could not be determined from the information provided by the customer.Based on the information available, there is no indication of a product deficiency.No corrective action is required at this time.
|